CHINA REGULATION SEMINAR AT OSAKA WITH XEDA AND FOSUN.

Posted by

November 29th, the theme of “China’s pharmaceutical industry development frontline” briefing was successfully held in Osaka, Japan. The event was hosted by Tianjin Xiqing Economic and Technological Development Zone and co-organized by the Kansai Pharmaceutical Association of Japan. More than 70 representatives from the Japanese pharmaceutical industry shared and exchanged views on the latest developments in China’s pharmaceutical industry and pharmaceutical policy reform. Explore the development trend and cooperation prospects of the Chinese and Japanese pharmaceutical industries.

The Kansai Pharmaceutical Association was originally the Osaka Medical Association. It has more than 300 pharmaceutical member companies, covering almost all of Japan’s large pharmaceutical companies.

The representative of the Japan office of the development zone, Mu Peng, introduced the latest development trend of Tianjin pharmaceutical industry, the investment environment of the pharmaceutical industry in Xiqing District and the development zone.

Next, the head of the Japanese business of FMDK&L Japan explained the policy reforms of the Chinese pharmaceutical industry and the latest developments in Japanese companies. At present, a series of pharmaceutical industry reforms are being carried out in China, which has improved the efficiency of IND & NDA and is a very good opportunity for Japanese companies to invest in China. She pointed out that Japanese pharmaceutical companies have great advantages in the field of new drug research and development. At present, the Chinese pharmaceutical market has surpassed Japan to become the world’s second-largest market and is growing rapidly. It is hoped that Japanese companies can seize opportunities and actively cooperate with local Chinese companies.

In the end, Mr Masaaki Sato, Senior Director of the Japanese Business Unit of Fosun Group, introduced the layout ofFosun Group in the big health industry and the recent cooperation with Japanese companies. Fosun Group is one of the world’s top 500 enterprises. Among them, the big health industry is its core industry. Mr Sato said that Fosun Group hopes to cooperate fully with Japanese pharmaceutical companies to provide abetter medical environment for Chinese patients. The medical industry briefing session was overwhelming. After the meeting, many companies actively spoke questions and expressed the hope that they would have the opportunity to develop in China.